Hyun Tae Lee

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Ju‐Yeun Lee, Hyun Tae Lee, Woo‐Ri Shin et al. · Nature Communications · 2016 · 289 citations · Full text

Pharmacy, Immunology, Oncology +17

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

Hyun Tae Lee, Ju‐Yeun Lee, Heejin Lim et al. · Scientific Reports · 2017 · 240 citations · Full text

Pharmacy, Oncology, Pharmacology +17

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus

Woo‐Ri Shin, Hyun Tae Lee, Heejin Lim et al. · Nature Communications · 2018 · 38 citations · Full text

Pharmacy, Immunology, Pharmacology +12

Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy

Sang Hyung Lee, Hyun Tae Lee, Heejin Lim et al. · Biochemical and Biophysical Research Communications · 2020 · 36 citations

Medicine, Oncology, Pharmacology +16

Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma

Hyun Tae Lee, Yu-Jin Kim, Ui Beom Park et al. · Biochemical and Biophysical Research Communications · 2020 · 36 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16